Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
Condition(s) studied
Investigational drug(s) / intervention(s)
oral glutamine: 10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
Maltodextrin: Maltodextrin
Study summary
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Eligibility
Primary outcome measure(s)
- Change of area of psoas muscle — 84 days after gastrectomy
area od psoas muscle on the CT scan
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| National Taiwan University Hospital | Taipei | Taiwan | Recruiting |
More National Taiwan University Hospital trials in Taiwan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06027242 on ClinicalTrials.gov ↗ ← All trials in Taiwan